AirCurveTM10 CS PaceWaveTM

The AirCurve 10 CS PaceWave is an adaptive servo-ventilator specifically designed to treat patients exhibiting central sleep apnea (CSA), mixed sleep apnea and periodic breathing, with or without obstructive sleep apnea

Featuring the most clinically-studied ASV algorithm, AirCurve 10 CS PaceWave is the only adaptive servo-ventilator that targets the patient’s own recent minute ventilation.

The device also features built-in wireless connectivity** so you can stay more connected to your patients than ever before.

** Wireless communication depends on network availability

ASVAuto mode

ASVAuto mode adapts to a patient’s ventilatory and upper airway stability needs on a breath-by-breath basis. By treating central breathing disorders with auto-adjusting Pressure Support and upper airway obstruction with auto-adjusting EPAP, it rapidly stabilises breathing and blood gases helping improve sleep quality.1,2

PaceWave is the most clinically studied ASV therapy.

AirCurve-10-ASV_KF_01_B2B

ASV mode

In ASV mode, the EPAP can be manually titrated to set the optimal fixed EPAP to keep the upper airway open.

AirCurve-10-ASV_KF_02_B2B_01

Other features

  • Easy-Breathe pressure waveform mimics the wave shape of normal breathing and replicates it for the patient’s breathing comfort.
  • Continuous leak management enables reliable delivery of therapy pressure while maintaining patient-device synchrony.
  • Climate Control comprises the HumidAir™ humidifier and the ClimateLineAir™ heated tube and is designed to deliver constant, comfortable temperature and humidity.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • subtitles off, selected
        2750693505001_3739427716001_vs-53f4256be4b0c980a3cfaf6f-672293880001

        Humidification (AU)

        For a fully integrated approach to patient care, prescribe ResMed Air Solutions products.

        Functional features

          AirCurve 10 CS PaveWave
        CPAP
        VAuto
        S mode  
        ASV
        ASVAuto
        Easy-Breathe waveform
        TiControl  
        Trigger and cycle  
        Climate Control
        Enhanced Climate Control Auto
        Vsync leak management
        Built-in wireless connectivity **

        * Wireless communication depends on network availability

        Technical specifications

        Dimensions (H x W x D) (Device and water tub)   116mm x 255mm x 150mm
        Weight 1248g
        Air filter Standard: Average arrestance: > 75% for ~7 micron dust

        Hypoallergenic: Efficiency: >98% for ~7-8 micron dust. >80% for ~0.5 micron dust.

        Aircraft use Meets Federal Aviation Administration requirements for all phases of air travel.
        Operating pressure range 4 to 20 cm H2O
        Pressure level measured according to ISO 17510-1:2007 (CPAP mode):
        SlimLine or Standard air tubing 26.6 dBA with uncertainty of 2 dBA
        Power level measured according to ISO 17510-1:2007 (CPAP mode):
        SlimLine or Standard air tubing 34.6 dBA with uncertainty of 2 dBA
        Sound (Declared dual-number noise emission values in accordance with ISO 4871:1996.)
        Air tubing ClimateLineTM Air SlimLineTM Standard
        Length 6'6” 6’ 6’.6”
        Inner diameter 0.6" 0.6" 0.75"
        Electromagnetic compatibility Complies with all EMC requirements according to IEC60601-1-2:2007 for residential, commercial and light industry environments. It is recommended that mobile communication devices be kept at least 1m away.

        References

        1

        Morgenthaler TI, Gay PC, Gordon N, Brown LK. Adaptive servoventilation versus noninvasive positive pressure ventilation for central, mixed, and complex sleep apnea syndromes. Sleep. 2007;30(4):468-475.

        2

        Brown SE, Mosko SS, Davis JA, Pierce RA, Godfrey-Pixton TV. A retrospective case series of adaptive servoventilation for complex sleep apnea. J Clin Sleep Med 2011;7(2):187-195.

        3
        *

        ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnea.